Articles in the Health Category
Posted in Health on 1 September 2010
Raritan, NJ – Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic osteoarthritis knee pain have been published by Clinical Drug Investigation. In addition, this study compared oxycodone controlled release (CR) to placebo as an active control. [...]
Posted in Health on 1 September 2010
Latest Results from EINSTEIN Program Presented at European Society of Cardiology Congress
Stockholm, SE — Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), announced today that the investigational, oral anticoagulant rivaroxaban successfully demonstrated non-inferiority compared to the standard of care1 for the prevention of recurrent venous thromboembolism (VTE) in patients with acute symptomatic deep vein [...]
Posted in Health on 23 August 2010
Designation expands global access of vaccine for the prevention of serious pneumococcal disease
NEW YORK — The World Health Organization (WHO) has granted prequalification to Prevenar 13* (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed])for active immunization of infants and children from 6 weeks through five years of age against invasive disease, pneumonia and otitis media caused by [...]
Posted in Health on 20 August 2010
Norderstedt, Germany — Ethicon Endo-Surgery (EES), has announced the introduction of a new addition to its HARMONIC® line of surgical devices, the HARMONIC ACE® 45 cm Curved Shears.
HARMONIC ACE® 45 cm, designed to extend the reach of surgeons for minimally invasive procedures involving obese patients, is 25 percent longer (or 9cm) than the standard length [...]
Posted in Health on 20 August 2010
Biggest improvement seen in children 10 years or older, especially in areas of Appearance, Activities, and Satisfaction with Vision Correction
Jacksonville, FL – Contact lenses improve vision-related quality of life in children compared with glasses, especially in the areas of appearance and athletics, according to data drawn from a three-year multi-site study assessing the effects [...]
Posted in Health on 20 August 2010
BEIJING – Beijing Goodwill Information and Technology Co., Ltd., a leading provider of electronic cardiogram systems in China, and IBM (NYSE: IBM) announced the launch of the country’s first all-in-one electronic cardiogram management system in China. This system supports smarter healthcare by helping hospitals to analyze patient information generated from electrocardiography (ECG) examination reports [...]
Posted in Health on 20 August 2010
Chalfont St. Giles, UK and Caesarea, Israel – GE Healthcare, a unit of General Electric Company (NYSE: GE), and Arineta Ltd. announced today the formation of a strategic partnership in the area of computed tomography (CT) for cardiovascular applications.
Cardiovascular disease (CVD) continues to be the leading cause of death globally and has an enormous impact [...]
Posted in Health on 18 August 2010
Seven Clinical Abstracts to be Presented Orally, Including Two-Year Phase 3 Data
PRINCETON, N.J. –Bristol-Myers Squibb Company (NYSE:BMY) announced today that belatacept, an investigational selective T cell co-stimulation blocker being studied for use in solid organ transplantation, will be the subject of seven oral clinical presentations related to kidney transplantation at the 23rd International Congress of [...]
Posted in Health on 18 August 2010
PRINCETON, N.J. –Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted, for filing and review, the Biologics License Application (BLA) for ipilimumab for the treatment of adult patients with advanced melanoma who have been previously treated. The company also announced today that the application has been granted [...]
Posted in Health on 14 August 2010
Chicago, IL – New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data [...]
